From: Trends in the use of antiasthmatic medications in Morocco (1999–2010)
1999 | 2006 | 2010 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AME | AME/GMW | NS | NP | AME | AME/GMW | NS | NP | AME | AME/GMW | NS | NP | |
Short-acting inhaled Beta-2-mimetic | 66.5 | 4.01 | 7 | 9 | 77.5 | 3.86 | 9 | 11 | 38.61 | 1.83 | 8 | 12 |
Long-acting inhaled Beta-2-mimetic | 425.5 | 25.64 | 2 | 3 | 265.04 | 13.19 | 3 | 4 | 209.17 | 9.92 | 2 | 2 |
Systemic Beta-2-mimetic | 76.4 | 4.60 | 4 | 14 | 68.61 | 3.41 | 7 | 18 | 71.27 | 3.38 | 6 | 13 |
Inhaled Glucocorticosteroids alone | 192.9 | 11.82 | 5 | 9 | 147.06 | 7.32 | 8 | 15 | 144.66 | 6.86 | 11 | 15 |
Association Beta-2-mimetic /Glucocorticosteroids | - | - | - | - | 363.02 | 18.07 | 2 | 6 | 209.20 | 9.92 | 4 | 13 |
Injectable Xanthines | 46.1 | 2.77 | 9 | 22 | 54.73 | 2.72 | 9 | 18 | 56.07 | 2.67 | 5 | 13 |
(161.40 ± 158.32) | (9.77 ± 9.55) | 27 | 57 | (162.66 ± 125.39) | (8.10 ± 6,24) | 38 | 72 | (121.5 ± 76.93) | (5.76 ± 3.65) | 36 | 68 |